In most eukaryotic cells, tubulin is subjected to posttranslational glutamylation, a conserved modification of unclear function. The glutamyl side chains form as branches of the primary sequence glutamic acids in two biochemically distinct steps: initiation and elongation. The length of the glutamyl side chain is spatially controlled and microtubule type specific. Here, we probe the significance of the glutamyl side chain length regulation in vivo by overexpressing a potent side chain elongase enzyme, Ttll6Ap, in Tetrahymena. Overexpression of Ttll6Ap caused hyperelongation of glutamyl side chains on the tubulin of axonemal, cortical, and cytoplasmic microtubules. Strikingly, in the same cell, hyperelongation of glutamyl side chains stabilized cytoplasmic microtubules and destabilized axonemal microtubules. Our observations suggest that the cellular outcomes of glutamylation are mediated by spatially restricted tubulin interactors of diverse nature.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2805296 | PMC |
| http://dx.doi.org/10.1128/EC.00176-09 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Short-term repeated oral intake of low dose cannabidiol: effects on liver enzyme activity and creatinine concentration during intense exercise.
Arch Toxicol
December 2024
Department of Molecular and Cellular Sports Medicine, Institute for Cardiovascular Research and Sports Medicine, German Sport University Cologne, Cologne, Germany.
The side effects and safety of cannabidiol (CBD) products are currently discussed in different contexts. Of all adverse effects, hepatotoxic effects have been reported most frequently in previous studies. However, the threshold for liver toxicity of CBD in humans is uncertain due to the lack of adequately designed studies in humans below the lowest observed adverse effect level (LOAEL) of 300 mg/day.
View Article and Find Full Text PDFpH-Responsive Charge-Reversal Smart Nanoparticles for Co-Delivery of Mitoxantrone and Copper Ions to Enhance Breast Cancer Chemo-Chemodynamic Combination Therapy.
Int J Nanomedicine
November 2024
College of Life Science, Zhuhai College of Science and Technology, Zhuhai, 519041, People's Republic of China.
Purpose: The poor delivery and limited penetration of nanoparticles into breast cancer tumors remain essential challenges for effective anticancer therapy. This study aimed to design a promising nanoplatform with efficient tumor targeting and penetration capability for effective breast cancer therapy.
Methods: A pH-sensitive mitoxantrone (MTO) and copper ion-loaded nanosystem functionalized with cyclic CRGDfK and r9 peptide (TPRN-CM) was rationally designed for chemo-chemodynamic combination therapy.
Loncastuximab tesirine in previously treated diffuse large B-cell lymphoma: A plain language summary of the LOTIS-2 study.
Future Oncol
November 2024
Department of Biomedical Sciences, Humanitas University, & Department of Oncology & Hematology, Humanitas Research Hospital-IRCCS, Milano, Italy.
What Is This Summary About?: This article provides a plain-language summary of the results of a clinical trial called the LOTIS-2 study.The LOTIS-2 study included 145 participants with an aggressive type (one that forms, grows, or spreads quickly) of non-Hodgkin lymphoma called diffuse large B-cell lymphoma (a type of blood cancer), or DLBCL for short, whose disease came back or did not respond after 2 or more previous treatments. The LOTIS-2 study was conducted from August 2018 to September 2022.
View Article and Find Full Text PDFNon-syndromic perspective on a unique progressive familial intrahepatic cholestasis variant: mutation.
Turk J Pediatr
October 2024
Division of Pediatric Gastroenterology, Department of Pediatrics, Gülhane Training and Research Hospital, Ankara, Türkiye.
Article Synopsis
- A recent discovery links the ZFYVE19 mutation to non-syndromic cholestasis, characterized by high gamma-glutamyl transferase levels, and potentially causing neonatal and intrahepatic cholestasis.
- A 4-year-old patient with a confirmed ZFYVE19 mutation, diagnosed at age 2, showed elevated liver enzymes but maintained normal liver function; treatment with ursodeoxycholic acid effectively reduced symptoms.
- Continued monitoring and whole exome sequencing (WES) are recommended to further understand the mutation's effects and possible liver complications in similar cases of unexplained liver issues.
Role of Growth Hormone Therapy in Metabolic-Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis.
Indian J Endocrinol Metab
August 2024
Department of Endocrinology, Mymensingh Medical College, Mymensingh, Bangladesh.
Multiple observation studies and meta-analysis have linked growth hormone (GH) deficiency with metabolic-dysfunction-associated steatotic liver disease (MASLD). No meta-analysis has analysed the efficacy and safety of GH therapy on different aspects of MASLD. We undertook this meta-analysis to address this gap in knowledge.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!